Insights
Insights From Our Experts
Articles
Supporting Successful Commercialization With Integrated Compliance
Compliance is an integral part of the entire biopharma, medical device and product lifecycle, yet it poses one of the biggest challenges for our customers. While they try to focus on driving value, innovation and patient…
Transforming Pharma With Industry-Leading Partnerships
EVERSANA is filling an influx of essential commercialization needs to overcome strained resources and support COVID-19 treatment launches. From groundbreaking treatments to long-overdue therapy improvements, there will be at least five new treatments headed to market…
Alternative Product Distribution Model: Where Agility Meets Profitability
The power of medicine is affecting current events more than ever as global well-being hinges on COVID-19 vaccines. As investments and research are poured into medical innovation, pharmaceutical manufacturers must decide how to get life-saving products…
A Time for Transition in Pharma: January 2021
So far, 2021 is proving to be a time for international transition in pharma. In the latest Pricentric INSIGHTS newsletter, we’re taking a closer look at new legislation and regulatory actions happening around the globe to…
Drug Pricing And Drug Price Reporting Regulatory Update
As the new president and Congress begin their terms, EVERSANA would like to provide an update on recent legislative and regulatory actions that affect drug pricing and price reporting. The Centers for Medicare and Medicaid Services…
Upcoming PharmaVOICE Panel – Next Gen Patient Services Models
With increasingly less face-to-face patient interaction, manufacturers need to rethink traditional solutions in order to alleviate access barriers. Despite best efforts, prescription rates continue to drop as newly launched products experience increased patient drop-off; and companies…
Key Factors to Obtaining Reimbursement for Digital Therapeutics in the U.S.
While wellness apps have been successful in a direct-to-consumer model, many digital therapeutics (DTx) providers are working to obtain reimbursement from U.S. payers. In a heterogenous payer ecosystem, the key question is how to obtain broad…
A Paul Simms Favorite: EVERSANA makes the list for 2021 Predictions
“Imagine there was a third way … an equivalent to the Apple App Store in our industry … maybe that model could start working in pharma; and, in fact, it is.” For pharmaceutical influencer Paul Simms,…
Leveraging Innovative Technology to Improve the Patient Journey
Commercial teams cannot afford to misinterpret the patient and product journeys. Over 50% of new launches fail to meet market forecasts. In addition, newly launched products are experiencing increased patient drop-off due to many U.S. market…
Under the Biden Team & Beyond COVID … What Lies Ahead for Healthcare
While the obvious healthcare focus for the new Biden/Harris Administration will be on controlling the COVID-19 pandemic, it’s a critical time to assess what lies beyond COVID for their attention. To gain a sense of what’s…